Merck's discount wins NICE nod for Keytruda; FDA flags user-error worries with Purdue's new painkiller;

> Merck & Co.'s ($MRK) new cancer immunotherapy Keytruda won backing from the U.K.'s cost-effectiveness watchdogs after offering an unspecified discount. Report

> FDA staff reviewers flagged likely errors in administering Purdue Pharma's new fast-acting oxycodone painkiller, saying taking the drug with food can interfere with its effectiveness. Report

> Canadian regulators cleared Recordati's rare disease drug Carbaglu for marketing, as a treatment for hyperammonemia. Report

> Two leading U.S. physicians' organizations say proposed megamergers in the health insurance business will be anti-competitive. Report

And Finally... U.K. life sciences groups, including pharma companies, urged the government not to cut research funding, citing the economic benefits of R&D work. Report

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.